

版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領
文檔簡介
1、Renal stenting in renal artery stenosis----contented and uncontented 腎 動 脈狹窄支架術,patients 發(fā)病率(%) General people
2、 0.1Hepertension 1-550y, wiht (ARAS) HT 15 CAD
3、 10-19 critical HT 30 HT+CAD 20-30 ESRD
4、 15-20 HT+CAD+PVD 40-60 HT+CAD+Renal dysfunction 40-60,,,Prevalence of renal artery stenosis (
5、RAS),ARAS 90%FMD 10%,Common causes of renal artery stenosis,HTRenal dysfunctionAngina pectorisParoxysmal acute pulmonary edema,Presentation of renal artery stenosis,Haemodynamics: >50% Renal perfusion pressure re
6、duction >70% RPP<75-85mmHg, autonomic regulation lose Pathology:Glomcrulus:arteriosclerosis, mesenterium proliferation,Nephric tubule:epithelial cells denudation、apoptosis,Focal necrosis,Renal interstitium:Inf
7、lammatory cell infiltration、fibrocyte proliferationEnd stage :renal atrophy,Atherosclerotic nephrosis,Natural course of ARAS,Develop to total occlusion within 5 years 15%Deterioration gradually within
8、 5 years 10-20%Develop to ESRD annually 5-15%3-year mortality in Pt. with ESRD on dislysis 50%Survival of ARAS Pt. with ESRD on dislysis:
9、 5-year 18% 10-year 5%,Atherosclerotic RAS progression,Conlon et al, Kidn
10、ey Int 2001 Oct;60:490-7Renal angio in 3987 Pt. undergoing cath,Independent predictor of mortality,Conlon et al, Kidney Int 2001 Oct;60:490-7Renal angio in 3987 Pt. undergoing cath,Independent predictor of mortality,Ca
11、se 1: male,62y,HT,,,Case 2: male, 78y,HT, DM, Renal dysfunction,Renal function:improement: GFR increse 15% /Scr decrease 0.2mg/dLstable: GFR change15% / Scr increase >0.2mg/dL benefit: Improement
12、or stableBlood pressure:cure: SBP 15mmHg with similar or less anti-hypertension drugsineffective: BP change not meet the above standardbenefit: cure and improvement,Stan
13、dard for prognosis evaluation after renal artery stenting (Rundback),Renal artery stenting success rate,PTRA on hepertension,PTRA on renal function,,Long-term effect of stenting on RAS,腎動脈支架術治療腎動脈狹窄患者的倪鈞 張瑞巖 胡健 張憲 鄭愛芳 沈
14、衛(wèi)峰上海交通大學附屬瑞金醫(yī)院心臟科(200025)摘要:目的: 評價腎動脈支架術治療腎動脈狹窄的長期療效。 方法:連續(xù)134例顯著腎動脈狹窄患者接受腎動脈支架術。記錄患者術前?術后24小時? 1年和2年長期的血清肌酐(sCr),和血壓變化情況。結果: 134例患者均成功置入支架,術后24小時肌酐較術前升高[(109.8±24.6)μmol/L比(99.4±27.8)μmol/L],腎小球濾過率 [(57.6
15、177;19.3)ml/min比(68.5±18.9)ml/min]較術前降低,但術后1年和2年的平均肌酐和術前比較差異無顯著性。腎動脈介入治療術后6月,64例血壓得到改善。術后1年的平均血壓為(148.6±22.6)mmHg,與術前比較有顯著性意義。術后1年和2年分別有56例(50.9%)和50例(49.6%)患者獲益。結論:腎動脈支架術治療腎動脈狹窄的遠期療效較好,且長期隨訪結果滿意。關鍵詞:動脈粥樣硬化;腎動
16、脈梗阻;介入治療,,,,,,,,,,,,,,,,,,Why some Pt. gain no benefit from RAS stenting?,,Renal parenchyma impairmentdiabetic nephropathyrenal impairment due to HTrenal impairment due to othersIschemic nephropathyAge CINRestenos
17、is,factors Influencing the outcomes in RAS underwent stent,nephron redunctionvolume-dependent hypertension:(Bil RAS/renal dysfunction) renin-dependent hypertension:(uni RAS)sympathetic nervous systemvasoactive substa
18、nce secreted from kidney:natriuretic hormone vasopressin,Mechanism of hypertension in CKD,Renal arteriolar sclerosis in benign hypertensio
19、nEarly stage:hyalinization in afferent glomerular arteriole and arteria interlobularesadvanced stage:glomerulus, nephric tubule, renal interstitium diseaserenal arteriolar sclerosis in malign
20、ant hypertension (DBP>120mmHg) Necroticarteriolitis, Proliferating endarteritis,Pathology of hypertension-induced renal impairment,Nephrosis dut to cholesterol crystal embolization,Epidemiology:,etiological fa
21、ctor:AS、endovascular procedure,,Henry (Percusurge)AJC Oct,2000 TCT30 RAS of 24 Pt. (27 ostial)All had renal impairement, 71% had HTSuccess rate 100%Occlusion time 418 sec(149-797),Embolization after stenting,Embo
22、lization after stenting,Improved renal function 46%Unchanged 4%Acute deterioration 0%No renal function deterioretion at 6 month6/30(20%) empty24/30(80%)had filter content
23、Chronic thrombusCholesterol cleftsfragment,Kidney in elderly,Kidney change vessel of kidney: renal arteriolar sclerosis renal glomerulus: normal adult 1.3 million, 1/3-1/2 lost in 70 year-old renal tubule:
24、 epithelial cell hypertrophia, renal interstitium: atrophy, fibrosisRenal function change renal blood flow:10% redunction per 10 years GFR:Among 40-80 year-old, GFR decrease 0.8-1ml/min every 1 year
25、,Kidney in elderly,Contrast induced nephrosis (CIN),Acute renal impairment after contrast applicationScr increase >44.2μmol/LOr, increase >25% compared to baselinePrevalence: unselected Pt. : 1-6 %,High risk
26、40-50 %,Risk factors related to CIN,Existed renal dysfunctionDMVascular diseaseElderly Lower EFhypovolemiadehydrationCongestive heart failurenephrotic syndrome; Liver Cirrhosis,Berg KJ, Scand J Urol Nephrol 2000;
27、 34: 317-322,Effect of DM and renal function on the incidence of CIN (n=1196),RI:renal impairment DM:diabetes Rudnick et al. (1995),,,,,,,,,,,,,,,,,0,5,10,15,20,25,+RI+DM,,+RI–DM,–RI+DM,–RI–D
28、M,0%,5.7%,19.7%,%,0.6%,Effect of DM and renal function on CIN with different contrast application,,,,,,,0,10,20,30,40,50,60,*定義為血清肌酐升高>44.2μmol/l或>25%(Laμtin et al. 應用的標準為>26.5μmol/l或>20%)**基線血清肌酐>133μmol/l(Barrett et al
29、. 的研究中>124μmol/l),,,,,,,,,,,,Patients (%),VisipaqueOmnipaqueorthers,,,,Aspelinet al.2003,Manskeet al.1990,Wanget al.2000,Rudnicket al.1995,Taliercioet al.1991,Lautinet al.1991,Barrettet al.1992,,,,,,,,Ren
30、al artery stenting restonosis,2006 AHA/ACC Guideline Indications for RAS Revascularization,(a) Asymptoatic Stenosis(Class IIb)1. asymptomatic bilateral or solitary viable kidney with a hemodynamically significant RAS.
31、 (Level of evidence: C) 2. asymptomatic unilateral hemodynamically significant RAS in a viable kidney is not well established and is presently clinically unproven. (Level of evidence: C)(b) Hypertension(Class IIa)hem
32、odynamically significant RAS and accelerated hypertension, resistant hypertension, malignant hypertension, hypertension with an unexplained unilateral small kidney, and hypertension with intolerance to medication. (Leve
33、l of evidence: B),J Vasc Interv Radiol. 2006 Sep;17(9):1383-97,,Preservation of Renal FunctionClass IIaRAS and progressive chronic kidney disease with bilateral RASor a RAS to a solitary functioning kidney. (Level of
34、evidence: B)Class IIbRAS and chronic renal insufficiency with unilateral RAS. (Level of evidence: C)Impact of RAS on Congestive Heart Failure and Unstable Angina Class Ihemodynamically significant RAS and recurrent
35、, unexplained congestive heart failure or sudden, unexplained pulmonary edema (Level of evidence: B)Class IIaPercutaneous revascularization is reasonable for patients with hemodynamically significant RAS and unstable
36、angina (Level of evidence: B),J Vasc Interv Radiol. 2006 Sep;17(9):1383-97,,Class IRenal stent placement is indicated for ostial atherosclerotic RAS lesions that meet the clinical criteria for intervention. (Level of
37、evidence: B)2. Balloon angioplasty with bailout stent placement if necessary is recommended for FMD lesions. (Level of evidence:B),J Vasc Interv Radiol. 2006 Sep;17(9):1383-97,Catheter-based Interventions for RAS,,BNP
38、increase is common in patients with hypertension Silva studyBaseline BNP>80pgml 77% Pts BP improved post procedure 30% 94% BP improved<30% 10% BP improved,Predictor for RAS s
39、tenting,,Doppler wireFFR≦0.8 BP and renal function improvePressure wire Distal renal/ Aorta80 97 % Pts. No BP improve 80 % Pts. No renal function improveIndicating : small vessel disease or renal parenc
40、hyma disease,,Total patients 240Requiring Renal revascularization Yes (20%)48 No (80%)192RRI (estimated) &
41、lt; 80 (2/3) ≥ 80 (1/3) < 80(2/3) ≥80 (1/3)N 32 16 128 64Randomized to revascularization Y/N
42、 Y/N 16/16 8/8,Purpose:1.compare renal revascularization to medical management for people with ARVD2.whether the RRI can identify patients with RAS who w
43、ill not benefit from renal revascularization procedures,Renal Athersosclerotic reVascularization Evaluation (RAVE Study),,High prevelence of RASHigh acute procedural success rateDifficult in evaluating the efficacy
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 腎動脈狹窄支架術中長期療效及相關因素分析.pdf
- 腎動脈狹窄腔內(nèi)血管成形術
- 腔內(nèi)支架治療移植腎動脈狹窄.pdf
- 經(jīng)皮腔內(nèi)腎動脈支架成形術治療動脈粥樣硬化性腎動脈狹窄的研究.pdf
- 腎動脈狹窄的超聲診斷
- 動脈粥樣硬化性腎動脈狹窄的經(jīng)皮腔內(nèi)腎動脈支架植入治療研究.pdf
- 腎動脈狹窄ras的治療進展
- 腎動脈狹窄(ras)的治療進展
- 支架術聯(lián)合規(guī)范藥物治療對粥樣硬化性腎動脈狹窄患者的療效.pdf
- 腎動脈狹窄支架血運重建對腎功能影響的研究.pdf
- 腎動脈狹窄診斷及介入治療
- 中國西部地區(qū)腎動脈支架植入手術治療腎動脈狹窄疾病患者的研究.pdf
- 顱內(nèi)動脈狹窄支架植入術病例分享
- 自體腎移植術治療腎動脈狹窄臨床分析(附9例報告).pdf
- 腎動脈狹窄的彩色多普勒超聲評價.pdf
- 重新審識腎動脈狹窄的介入治療
- 血流動力指標和腎素對動脈粥樣硬化性腎動脈狹窄支架術療效預測價值研究.pdf
- 超聲對腎動脈狹窄介入術后療效的評價及超聲造影診斷腎動脈狹窄的應用研究.pdf
- 超聲評價腎動脈狹窄的實驗研究.pdf
- 國內(nèi)頸動脈狹窄內(nèi)膜剝脫術現(xiàn)狀分析.pdf
評論
0/150
提交評論